EAST SETAUKET, N.Y., Oct. 20 /PRNewswire-FirstCall/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT), announces the appointment of Mel Sorensen, M.D. to the company's Board of Directors.
Dr. Sorensen is currently Board Director, President and Chief Executive Officer of Ascenta Therapeutics. He is a highly experienced leader and administrator in cancer therapeutics and cancer drug development.
Trained as a medical oncologist, Dr. Sorensen has dedicated his career to clinical cancer research and cancer drug development. After completing his oncology fellowship at the Mayo Clinic, Rochester, MN in 1988, Dr. Sorensen spent seven years at the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). At CTEP, he managed collaborations between companies developing new anti-cancer agents and academic clinics and clinical cooperative groups. He had responsibility for over 40 research compounds.
Following NCI, Dr. Sorensen spent nearly eight years at large pharmaceutical companies in leadership roles in oncology clinical development and medical affairs. He established Bayer's first clinical oncology department and oversaw multiple clinical trials (Phase 1, 2 and 3) of novel agents. He subsequently joined GlaxoSmithKline (GSK) as Vice-President, Global Leader and North American Head of Clinical Development and Medical Affairs for Oncology, where he recruited a large team of physicians and scientists and led global clinical development of chemotherapeutic agents. While at GSK and Bayer, he was very active in business development, facilitating several in-licensing agreements and joint collaborations (including Onyx, SB, Corixa, Nippon Kayaku, and Hoffmann-La Roche).
Dr. Sorensen joined Ascenta Therapeutics in August 2004. Under his
leadership, in less than three years Ascenta was transformed from a
5-person start-up with a single preclinical program int
|SOURCE Lixte Biotechnology Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved